

U.S. Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Biologics), By Synthesis (Synthetic, Biotech), By Drug (Innovative, Generics), By Application (Oncology, Glaucoma), By Workflow, And Segment Forecasts, 2025 - 2033

<https://marketpublishers.com/r/U52F3289B02FEN.html>

Date: September 2025

Pages: 150

Price: US\$ 5,950.00 (Single User License)

ID: U52F3289B02FEN

Abstracts

Market Size & Trends

The U.S. active pharmaceutical ingredient CDMO market size was estimated at USD 36.39 billion in 2024 and is projected to reach USD 72.65 billion by 2033, growing at a CAGR of 8.09% from 2025 to 2033. The market is propelled by the presence of several biopharmaceutical companies globally, the growing demand for advanced and high-potency active pharmaceutical ingredient (APIs), and the trend of outsourcing to lower costs and speed time to market. Moreover, the increasing demand for generics, fueled by the patent expiry of blockbuster drugs, is also creating significant opportunities for the CDMOs.

In addition, the growing biologics and biosimilars pipeline that requires capabilities in large-scale fermentation and cell culture is also driving the market growth. A shift toward personalization of medicine has driven pharmaceutical companies to increasingly seek out CDMOs capable of delivering flexibly scheduled, highest quality manufacturing solutions for niche patient populations. Moreover, the increasing incidence of chronic diseases such as cancer and cardiovascular conditions is driving demand for space in new drug delivery systems, further increasing dependence on CDMOs that can not only provide technical feasibility but also regulatory expertise.

Furthermore, pharmaceutical companies increasingly prioritize optimized supply chains and strict FDA compliance, making domestic CDMOs a key partner in the U.S. market. Outsourcing production allows businesses to control expenses, safeguard intellectual property, and get through the regulatory approval process more quickly than if they use offshore providers. Furthermore, increased investment from the U.S. in green chemistry, sustainable manufacturing, and eco-friendly practices drives global pharma players' demand for U.S.-based CDMOs.

U.S. Active Pharmaceutical Ingredient CDMO Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. active pharmaceutical ingredient CDMO market report based on product, synthesis, drug, application, and workflow.

Product Outlook (Revenue, USD Million, 2021 - 2033)

Traditional Active Pharmaceutical Ingredient (Traditional API)

Highly Potent Active Pharmaceutical Ingredient (HP-API)

Biologics

Synthesis Outlook (Revenue, USD Million, 2021 - 2033)

Synthetic

Biotech

Drug Outlook (Revenue, USD Million, 2021 - 2033)

Innovative

Generics

Workflow Outlook (Revenue, USD Million, 2021 - 2033)

Clinical

Commercial

Application Outlook (Revenue, USD Million, 2021 - 2033)

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Others

This report can be delivered to the clients within 2 Business Days

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Value chain based analysis (Model 2)
 - 1.7.3. Multivariate Analysis (Model 3)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot

CHAPTER 3. U.S. ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: VARIABLES, TRENDS, & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent Market Outlook
 - 3.1.2. Ancillary Market Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Impact Analysis
 - 3.2.2. Market Restraint Analysis
- 3.3. Technological Landscape

- 3.4. Pricing Model Analysis
- 3.5. Regulatory Framework
- 3.6. Supply Chain Analysis
- 3.7. Tariff Impact Analysis
- 3.8. Market Analysis Tools
 - 3.8.1. Porter's Five Forces Analysis
 - 3.8.2. PESTEL by SWOT Analysis

CHAPTER 4. U.S. ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: PRODUCT ESTIMATES & TREND ANALYSIS

- 4.1. Segment Dashboard
- 4.2. U.S. Active Pharmaceutical Ingredient CDMO Market Product Movement Analysis
- 4.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Traditional Active Pharmaceutical Ingredient (Traditional API)
 - 4.4.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD million)
- 4.5. Highly Potent Active Pharmaceutical Ingredient (HP-API)
 - 4.5.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Biologics
 - 4.6.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 5. U.S. ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: SYNTHESIS ESTIMATES & TREND ANALYSIS

- 5.1. Segment Dashboard
- 5.2. U.S. Active Pharmaceutical Ingredient CDMO Market Synthesis Movement Analysis
- 5.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Synthesis, 2021 to 2033 (USD Million)
- 5.4. Synthetic
 - 5.4.1. Synthetic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Biotech
 - 5.5.1. Biotech Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 6. U.S. ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: DRUG ESTIMATES & TREND ANALYSIS

- 6.1. Segment Dashboard
- 6.2. U.S. Active Pharmaceutical Ingredient CDMO Market Drug Movement Analysis
- 6.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Million)
- 6.4. Innovative
 - 6.4.1. Innovative Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Generics
 - 6.5.1. Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 7. U.S. ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: APPLICATION ESTIMATES & TREND ANALYSIS

- 7.1. Segment Dashboard
- 7.2. U.S. Active Pharmaceutical Ingredient CDMO Market Application Movement Analysis
- 7.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 7.4. Oncology
 - 7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Hormonal
 - 7.5.1. Hormonal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Glaucoma
 - 7.6.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Cardiovascular disease
 - 7.7.1. Cardiovascular disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Diabetes
 - 7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9. Others
 - 7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 8. U.S. ACTIVE PHARMACEUTICAL INGREDIENT CDMO MARKET: WORKFLOW ESTIMATES & TREND ANALYSIS

- 8.1. Segment Dashboard
- 8.2. U.S. Active Pharmaceutical Ingredient CDMO Market Workflow Movement Analysis
- 8.3. U.S. Active Pharmaceutical Ingredient CDMO Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)

8.4. Clinical

8.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

8.5. Commercial

8.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)

CHAPTER 9. COMPETITIVE LANDSCAPE

9.1. Company Categorization

9.1.1. Market Leaders

9.1.2. Emerging Players

9.2. Company Market Share/Assessment Analysis, 2024

9.3. Company Profiles

9.3.1. Cambrex Corporation

9.3.1.1. Company Overview

9.3.1.2. Financial Performance

9.3.1.3. Product/Service Benchmarking

9.3.1.4. Strategic Initiatives

9.3.2. Recipharm AB

9.3.2.1. Company Overview

9.3.2.2. Financial Performance

9.3.2.3. Product/Service Benchmarking

9.3.2.4. Strategic Initiatives

9.3.3. Thermo Fisher Scientific Inc.

9.3.3.1. Company Overview

9.3.3.2. Financial Performance

9.3.3.3. Product/Service Benchmarking

9.3.3.4. Strategic Initiatives

9.3.4. CordenPharma International

9.3.4.1. Company Overview

9.3.4.2. Financial Performance

9.3.4.3. Product/Service Benchmarking

9.3.4.4. Strategic Initiatives

9.3.5. Samsung Biologics

9.3.5.1. Company Overview

9.3.5.2. Financial Performance

9.3.5.3. Product/Service Benchmarking

9.3.5.4. Strategic Initiatives

9.3.6. Lonza

9.3.6.1. Company Overview

- 9.3.6.2. Financial Performance
- 9.3.6.3. Product/Service Benchmarking
- 9.3.6.4. Strategic Initiatives
- 9.3.7. Catalent, Inc.
 - 9.3.7.1. Company Overview
 - 9.3.7.2. Financial Performance
 - 9.3.7.3. Product/Service Benchmarking
 - 9.3.7.4. Strategic Initiatives
- 9.3.8. Siegfried Holding AG
 - 9.3.8.1. Company Overview
 - 9.3.8.2. Financial Performance
 - 9.3.8.3. Product/Service Benchmarking
 - 9.3.8.4. Strategic Initiatives
- 9.3.9. Piramal Pharma Solutions
 - 9.3.9.1. Company Overview
 - 9.3.9.2. Financial Performance
 - 9.3.9.3. Product/Service Benchmarking
 - 9.3.9.4. Strategic Initiatives
- 9.3.10. Boehringer Ingelheim International GmbH
 - 9.3.10.1. Company Overview
 - 9.3.10.2. Financial Performance
 - 9.3.10.3. Product/Service Benchmarking
 - 9.3.10.4. Strategic Initiatives

List Of Tables

LIST OF TABLES

Table 1 List of abbreviation

Table 2 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)

Table 3 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Synthesis, 2021 - 2033 (USD Million)

Table 4 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Drugs, 2021 - 2033 (USD Million)

Table 5 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)

Table 6 U.S. Active Pharmaceutical Ingredient CDMO Market Estimates and Forecasts, by Workflow, 2021 - 2033 (USD Million)

List Of Figures

LIST OF FIGURES

- Fig. 1 US Active Pharmaceutical Ingredient CDMO Market segmentation
- Fig. 2 Market research process
- Fig. 3 Information procurement
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Market formulation & validation
- Fig. 7 Commodity flow analysis
- Fig. 8 Value-Chain-Based Sizing & Forecasting
- Fig. 9 QFD model sizing & forecasting
- Fig. 10 Bottom-up approach
- Fig. 11 Market snapshot
- Fig. 12 Segment snapshot
- Fig. 13 Segment snapshot
- Fig. 14 Segment snapshot
- Fig. 15 Competitive landscape snapshot
- Fig. 16 Parent market outlook, 2024 (USD Million)
- Fig. 17 Ancillary market outlook, 2024 (USD Million)
- Fig. 18 US Active Pharmaceutical Ingredient CDMO Market dynamics
- Fig. 19 Total R&D drug pipeline size, 2021-2024
- Fig. 20 Total drug pipeline by development phase, 2024
- Fig. 21 Porter's five forces analysis
- Fig. 22 PESTEL analysis
- Fig. 23 US Active Pharmaceutical Ingredient CDMO Market Product outlook: Segment dashboard
- Fig. 24 US Active Pharmaceutical Ingredient CDMO Market, by Product segment: Market share, 2025 & 2033
- Fig. 25 Traditional Active Pharmaceutical Ingredient (Traditional API) market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 26 Highly Potent Active Pharmaceutical Ingredient (HP-API) market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 27 Biologics market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 28 Others market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 29 US Active Pharmaceutical Ingredient CDMO Market Synthesis outlook: Segment dashboard
- Fig. 30 Active Pharmaceutical Ingredient CDMO Market, by Synthesis segment: Market

share, 2025 & 2033

Fig. 31 Synthetic market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 32 Biotech market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 33 US Active Pharmaceutical Ingredient CDMO Market Drug outlook: Segment dashboard

Fig. 34 Active Pharmaceutical Ingredient CDMO Market, by Drug segment: Market share, 2025 & 2033

Fig. 35 Innovative market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 36 Generics market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 37 US Active Pharmaceutical Ingredient CDMO Market Application outlook: Segment dashboard

Fig. 38 Active Pharmaceutical Ingredient CDMO Market, by Application segment: Market share, 2025 & 2033

Fig. 39 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 40 Hormonal market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 41 Glaucoma market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 42 Cardiovascular disease market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 43 Diabetes market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 44 Others market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 45 US Active Pharmaceutical Ingredient CDMO Market Workflow outlook: Segment dashboard

Fig. 46 Active Pharmaceutical Ingredient CDMO Market, by Workflow segment: Market share, 2025 & 2033

Fig. 47 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 48 Commercial market estimates and forecasts, 2021 - 2033 (USD Million)

Fig. 49 Market participant categorization

Fig. 50 Heat map analysis

I would like to order

Product name: U.S. Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Traditional API, HP-API, Biologics), By Synthesis (Synthetic, Biotech), By Drug (Innovative, Generics), By Application (Oncology, Glaucoma), By Workflow, And Segment Forecasts, 2025 - 2033

Product link: <https://marketpublishers.com/r/U52F3289B02FEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U52F3289B02FEN.html>